ENA-001

ENA-001
Clinical data
Routes of; administration	IV
ATC code	None;
Legal status
Legal status	US: Investigational New Drug;
Identifiers
	IUPAC name 2-[(N-Methyl-N-methoxy)amino]-4,6-bis(propylamino)-1,3,5-triazine;
CAS Number	1380341-99-0;
PubChem CID	57340959;
ChemSpider	62866096;
UNII	4RZ4OGT40Z;
CompTox Dashboard (EPA)	DTXSID601031220 ;
Chemical and physical data
Formula	C11H22N6O
Molar mass	254.338 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCNc1nc(nc(N(C)OC)n1)NCCC;
	InChI InChI=1S/C11H22N6O/c1-5-7-12-9-14-10(13-8-6-2)16-11(15-9)17(3)18-4/h5-8H2,1-4H3,(H2,12,13,14,15,16); Key:FJNLCHNQVJVCPY-UHFFFAOYSA-N;

ENA-001 (formerly GAL-021)^[1] is a drug related to almitrine which acts as a respiratory stimulant, with its mechanism of action primarily thought to involve blocking the BK_Ca potassium channel,^[2] although secondary mechanisms may also be involved.^[3] It was developed by Galleon Pharmaceuticals, and is being tested in clinical trials for potential uses in post-operative care,^[4] as well as more generally to counteract the respiratory depression which can be a side effect of opioid analgesic drugs.^[5]^[6]^[7]

Quick facts Clinical data, Routes ofadministration ...

See also